This clinical trial focuses on treating patients with gastric peritoneal metastases, a condition where cancer from the stomach has spread to the lining of the abdominal cavity. The study evaluates a treatment combining irinotecan, a cancer medication, given directly into the abdominal cavity (through a procedure called intraperitoneal administration) along with other standard cancer treatments given through the bloodstream.
The purpose of the study is to determine if it is possible to safely give irinotecan directly into the abdominal cavity while patients are receiving their regular cancer treatment. The study will last approximately 18 months for each participant. During this time, patients will receive multiple treatment cycles combining intraperitoneal irinotecan with their standard cancer therapy.
The medication being tested, irinotecan, belongs to a group of drugs called DNA topoisomerase I inhibitors, which work by interfering with cancer cell growth. The treatment will be given at doses up to 75 milligrams per day, with a maximum total dose of 600 milligrams over the course of treatment. Researchers will monitor how well patients tolerate the treatment and track their progress throughout the study period.
The Netherlands 
